J. Huggins

发表

Dual-probe real-time PCR assay for detection of variola or other orthopoxviruses with dried reagents

P. Jahrling, M. Aitichou, S. Saleh, 2008, Journal of virological methods.

A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

M. Bray, J. Huggins, C. Schmaljohn, 1998, The Journal of infectious diseases.

Smallpox and pan-Orthopox Virus Detection by Real-Time 3′-Minor Groove Binder TaqMan Assays on the Roche LightCycler and the Cepheid Smart Cycler Platforms

D. Norwood, P. Jahrling, R. Baker, 2004, Journal of Clinical Microbiology.

DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.

P. Jahrling, M. Bray, D. Fuller, 1998, Virology.

Cynomolgus Macaque as an Animal Model for Severe Acute Respiratory Syndrome

T. Slezak, R. Baric, D. Norwood, 2006, PLoS medicine.

Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.

D. Relman, P. Jahrling, K. Rubins, 2004, Proceedings of the National Academy of Sciences of the United States of America.

A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system.

M. Bray, J. Huggins, M. Martinez, 2000, Archives of pathology & laboratory medicine.

Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.

C. Goldsmith, J. Huggins, S. Nichol, 2005, Virology.

Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride.

T. Monath, J. Huggins, M. Phelan, 1992, Journal of medicinal chemistry.

Activity of a methanolic extract of Zimbabwean Crinum macowanii against exotic RNA viruses in vitro

J. Huggins, Z. J. Duri, J. Scovill, 1994 .

Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges

Christiana N. Fogg, P. Earl, B. Moss, 2007, Vaccine.

Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.

D. Venzon, Mark G. Lewis, M. Bray, 2005, The Journal of infectious diseases.

Ribavirin mitigates wart growth in rabbits at early stages of infection with cottontail rabbit papillomavirus.

P. Schlievert, J. Huggins, R. Mcglennen, 1992, Antiviral research.

Ribavirin therapy for Hantaan virus infection in suckling mice.

J. Huggins, G. R. Kim, K. Mckee, 1986, The Journal of infectious diseases.

An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge

R. Jordan, R. Baker, R. Buller, 2005, Journal of Virology.

Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug.

J. Huggins, 1989, Reviews of infectious diseases.

Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus.

M. Bray, J. Huggins, S. Hatfill, 2001, Journal of comparative pathology.

Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea☆

T. Cosgriff, J. Huggins, J. Rusnak, 2008, Antiviral Research.

Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome.

J. Leduc, T. Cosgriff, J. Huggins, 1991, The Journal of infectious diseases.

HANTAAN VIRUS, AETIOLOGICAL AGENT OF KOREAN HAEMORRHAGIC FEVER, HAS BUNYAVIRIDAE-LIKE MORPHOLOGY

J. Huggins, H. W. Lee, O. Brand, 1982, The Lancet.

Validation of a pan-orthopox real-time PCR assay for the detection and quantification of viral genomes from nonhuman primate blood

J. Huggins, Eric M. Mucker, Chris Hartmann, 2017, Virology Journal.

Comparative whole genome sequence analysis of wild-type and cidofovir-resistant monkeypoxvirus

J. Huggins, J. Farlow, M. Ichou, 2010, Virology Journal.

Differentiation of Variola major and Variola minor variants by MGB-Eclipse probe melt curves and genotyping analysis.

J. Huggins, D. Kulesh, Bonnie M. Loveless, 2009, Molecular and cellular probes.

Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models

J. Huggins, T. Endy, Chris Hartmann, 2005, Antiviral Research.

Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever

J. Huggins, K. Mckee, B. G. Mahlandt, 1988, Antimicrobial Agents and Chemotherapy.

The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus.

M. Bray, J. Mcmahon, J. Huggins, 2014, Antiviral research.

Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model.

M. Bray, J. Huggins, Z. Zhang, 1999, The Journal of infectious diseases.

Characterization of the binding of the TC-83 strain of Venezuelan Equine encephalomyelitis virus to BW-J-M, a mouse macrophage-like cell line.

P. Jahrling, J. Huggins, C. D. Linden, 1983, The Journal of general virology.

Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor.

M. Bray, J. Huggins, J. Driscoll, 2000, Antiviral research.

Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246

Chelsea M. Byrd, J. Shamblin, R. Jordan, 2009, Antimicrobial Agents and Chemotherapy.

Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.

P. Earl, B. Moss, D. Montefiori, 2007, Virology.

Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease

J. Shamblin, L. Hensley, J. Huggins, 2015, PloS one.

SMALLPOX AND RELATED ORTHOPOXVIRUSES

P. Jahrling, M. Ibrahim, J. Huggins, 2009 .

Potential Role of Immunomodulators for Treatment of Phlebovirus Infections of Animals a

D. Smee, M. Kende, J. Huggins, 1992, Annals of the New York Academy of Sciences.

Prophylactic and therapeutic activities of 7-thia-8-oxoguanosine against Punta Toro virus infections in mice

D. Smee, J. Huggins, R. Sidwell, 1991, Antiviral Research.

Progression of Pathogenic Events in Cynomolgus Macaques Infected with Variola Virus

P. Jahrling, K. Rubins, L. Hensley, 2011, PloS one.

The challenges of developing an antiviral agent for the treatment of smallpox using the animal efficacy rule

R. Moyer, J. Huggins, G. Painter, 2006 .

ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification

Chelsea M. Byrd, J. Shamblin, R. Jordan, 2009, Antimicrobial Agents and Chemotherapy.

Smallpox Research Activities: U.S. Interagency Collaboration, 2001

D. Relman, P. Jahrling, J. Leduc, 2002, Emerging infectious diseases.

In-vivo activity of antivirals against exotic RNA viral infections.

M. Kende, J. Huggins, P. G. Canonico, 1984, The Journal of antimicrobial chemotherapy.

Characterization of Wild-Type and Cidofovir-Resistant Strains of Camelpox, Cowpox, Monkeypox, and Vaccinia Viruses

D. Smee, M. Bray, J. Huggins, 2002, Antimicrobial Agents and Chemotherapy.

Antiviral Activity and Mode of Action Studies of Ribavirin and Mycophenolic Acid against Orthopoxviruses in Vitro

D. Smee, M. Bray, J. Huggins, 2001, Antiviral chemistry & chemotherapy.

Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances.

T. Monath, M. Hollingshead, J. Huggins, 1992, Journal of natural products.

Activity of Selected Amaryllidaceae Constituents and Related Synthetic Substances Against Medically Important RNA Viruses

T. Monath, M. Hollingshead, J. Huggins, 1992 .

Pharmacokinetics of the antiviral agent 3-deazaneplanocin A

R. Coulombe, J. Huggins, R. Sharma, 1995, European Journal of Drug Metabolism and Pharmacokinetics.

Practical synthesis of D- and l-2-cyclopentenone and their utility for the synthesis of carbocyclic antiviral nucleosides against orthopox viruses (smallpox, monkeypox, and cowpox virus).

C. K. Chu, J. Huggins, Peng Liu, 2003, The Journal of organic chemistry.

Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells.

P. Jahrling, J. Huggins, T. Geisbert, 1997, Archives of pathology & laboratory medicine.

Experimental infection of guinea pigs with Venezuelan hemorrhagic fever virus (Guanarito): a model of human disease.

P. Jahrling, J. Huggins, T. Geisbert, 1996, The American journal of tropical medicine and hygiene.

Antiviral activity of cyclopentenyl nucleosides against orthopox viruses (Smallpox, monkeypox and cowpox)

R. Baker, C. K. Chu, J. Huggins, 2002, Bioorganic & medicinal chemistry letters.

Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.

M. Bray, J. Huggins, A. Pletnev, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections

M. Bray, R. Baker, J. Huggins, 2003, Antiviral research.

N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors.

R. Jordan, R. Baker, J. Huggins, 2007, Journal of medicinal chemistry.

Antiviral Therapy of Haemorrhagic Fevers and Arbovirus Infections

M. Bray, J. Huggins, 1998 .

Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent

B. K. Murray, R. K. Robins, J. Huggins, 1983, Antimicrobial Agents and Chemotherapy.

Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses

R. K. Robins, J. Huggins, F. Detrick, 1984, Antimicrobial Agents and Chemotherapy.

Maternal and Fetal Outcomes Among Pregnant Women With Human Monkeypox Infection in the Democratic Republic of Congo

J. Muyembe, J. Huggins, P. Mulembakani, 2017, The Journal of infectious diseases.

Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge.

D. Smee, M. Bray, E. Thompson, 2000, The Journal of infectious diseases.

Monkeypox virus detection in rodents using real-time 3′-minor groove binder TaqMan® assays on the Roche LightCycler

D. Norwood, J. Huggins, C. Rossi, 2004, Laboratory Investigation.

Clinical characterization of human monkeypox infections in the Democratic Republic of the Congo

J. W. Martin, J. Huggins, A. Honko, 2022, medRxiv.

Genomic Variability of Monkeypox Virus among Humans, Democratic Republic of the Congo

Jeffrey R. Kugelman, B. S. Schneider, N. Wolfe, 2014, Emerging infectious diseases.

In vitro and in vivo antiviral (RNA) evaluation of orotidine 5′-monophosphate decarboxylase inhibitors and analogues including 6-azauridine-5′-(ethyl methoxyalaninyl)phosphate (a 5′-monophosphate prodrug)

T. Monath, D. Smee, J. Huggins, 1994 .

Biological Response Modifiers in Combination with Antivirals against Experimentally-Induced Virus Infections

D. Smee, R. K. Robins, M. Kende, 1992 .

Inhibition of Monkeypox virus replication by RNA interference

P. Jahrling, J. Huggins, Eric M. Mucker, 2009, Virology Journal.

Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.

P. Jahrling, J. Leduc, M. Bray, 1999, The Journal of infectious diseases.

Chapter 24 SMALLPOX AND RELATED ORTHOPOXVIRUSES

M. Ibrahim, J. Huggins, S. Johnston, 2018 .

The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model.

Adeline R. Whitney, Kathleen H Rubins, Lisa E Hensley, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses.

P. Jahrling, J. Leduc, C. Peters, 1996, Archives of virology. Supplementum.

RNA Viruses that Cause Hemorrhagic, Encephalitic, and Febrile Disease

J. Huggins, 1990 .

Inhibition of Ebola Virus by S-Adenosylhomocysteine Hydrolase Inhibitors

R. Coulombe, J. Huggins, Z. Zhang, 1995 .

A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

M. Bray, J. Huggins, C. Schmaljohn, 1998, The Journal of infectious diseases.

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

P. Earl, B. Moss, P. Jahrling, 2004, Nature.

Interferon-β 1a and SARS Coronavirus Replication

Peter B. Jahrling, Christopher Karp, Lisa E. Hensley, 2004, Emerging infectious diseases.

Countermeasures to the Reemergence of Smallpox Virus as an Agent of Bioterrorism

P. Jahrling, J. Huggins, G. Zaucha, 2000 .

Antibodies to Puumala virus in humans determined by neutralization test.

Å. Lundkvist, J. Huggins, B. Niklasson, 1992, Journal of virological methods.

Design and Optimization of a Monkeypox virus Specific Serological Assay

I. Damon, J. Huggins, M. Reynolds, 2023, Pathogens.

Intracellular Phosphorylation of Carbocyclic 3-Deazaadenosine, an Anti-Ebola Virus Agent

D. Smee, M. Bray, J. Huggins, 2001, Antiviral chemistry & chemotherapy.

Pharmacokinetics of the antiviral agent carbocyclic 3-deazaadenosine.

R. Coulombe, J. Huggins, J. Huie, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Inhibition of ebola virus replication in vitro and in a SCID mouse model by S-adenosylhomocysteine hydrolase inhibitors

T. Monath, J. Huggins, Z. Zhang, 1991 .

IN VITRO ANTIVIRAL ACTIVITY OF HUMAN RHINOVIRUS 3C PROTEASE INHIBITORS AGAINST THE SARS CORONAVIRUS

D. Matthews, P. Rejto, P. W. Rose, 2004 .

Clinical characterization and placental pathology of mpox infection in hospitalized patients in the Democratic Republic of the Congo

J. Huggins, M. Reynolds, A. Honko, 2023, PLoS neglected tropical diseases.

Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response.

M. Kortepeter, Sung‐Han Kim, J. Huggins, 2015, Vaccine.

Smallpox research activities

D. Relman, P. Jahrling, J. Leduc, 2002 .

Successful Treatment in the Monkeypox and Variola Primate Models of Smallpox by the Oral Drug ST-246

R. Jordan, J. Huggins, D. Hruby, 2007 .

Inhibition of RNA Viruses In Vitro and in Rift Valley Fever-Infected Mice by Didemnins A and B

J. Huggins, P. G. Canonico, W. L. Pannier, 1982, Antimicrobial Agents and Chemotherapy.

Inhibition of Phlebovirus Infections in vivo by Tiazofurin and Selenazofurin

J. Huggins, J. Huffman, L. L. Hall, 1990 .

Maternal and Fetal Outcomes Among Pregnant Women With Human Monkeypox Infection in the Democratic Republic of Congo.

J. Muyembe, J. Huggins, P. Mulembakani, 2017, The Journal of infectious diseases.

Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge

M. Bray, B. Meyer, J. Huggins, 1997, Journal of virology.